Off-the-Shelf CAR T-Cell Therapy P-BCMA-ALLO1 Is Efficacious in Relapsed/Refractory Multiple Myeloma

Pomalidomide Combo Sustains Improved Outcomes in Pretreated R/R Myeloma

Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.

Immunomodulators (IMDs) Today - Patient Empowerment Network

A panel of experts discuss the bedrock therapy in multiple myeloma immunomodulators (IMDs). The panel includes: Jenny Ahlstrom – Founder and Chief Executive Officer, Healthtree Foundation Diane Moran – Business […] The post Immunomodulators (IMDs) Today appeared first on Patient Empowerment Network.

First relapse in multiple myeloma: the patient perspective

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

Off-the-Shelf CAR T-Cell Therapy P-BCMA-ALLO1 Is Efficacious in Relapsed/Refractory Multiple Myeloma

P-BCMA-ALLO1 displayed high response rates and compelling safety in a heavily pretreated population of patients with relapsed/refractory multiple myeloma.

Elotuzumab-Based Regimen Demonstrates Efficacy in Relapsed/Refractory Multiple Myeloma

A phase 2 study showed that elotuzumab combined with pomalidomide, bortezomib, and dexamethasone was safe and efficacious.

Quantifying high-risk chromosomal aberrations predicts multiple myeloma prognosis

By Lynda Williams, medwireNews ReportermedwireNews: The presence of two or more high-risk chromosomal aberrations in patients with multiple myeloma is associated with an especially poor outcome throughout the disease course, shows research published in the Journal of Clinical Oncology.This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.Read the full story on the L’Institut Servier websiteIm…